The short answer
Retatrutide is a lipidated 39-residue peptide of approximately 4,731 Da, supplied as a white lyophilised powder. Its fatty-acid chain makes it amphipathic, which affects solubility behaviour in ways an unmodified peptide of the same length would not show.
Key facts
- Physical form
- White lyophilised powder
- Residues
- 39
- Reported MW
- ~4,731 Da
- Lipid
- C20 diacid at Lys17
- Character
- Amphipathic
- Class
- Lipidated peptide
What lipidation does to physical behaviour
Attaching a twenty-carbon diacid to a peptide creates a molecule with a hydrophilic peptide portion and a hydrophobic tail. Amphipathic molecules behave differently from either extreme: they orient at interfaces, they can self-associate above a threshold concentration, and their solubility is more sensitive to buffer composition than an unmodified peptide's.
Why that matters at interfaces
All peptides denature at air-liquid interfaces, which is why shaking is discouraged. A lipidated peptide is more surface-active than most, because the hydrophobic tail actively drives it to the interface. Foaming is therefore more consequential here than for a highly hydrophilic short peptide such as Selank or TB-500.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Composition and analysis
At 39 residues on a GIP scaffold the peptide contains aromatic residues, so absorbance near 280 nm is available for quantification. Unlike several shorter peptides in this library that lack any aromatic residue. Mass spectrometry against the stated mass is the identity check, with the caveat that the expected value itself is reported rather than database-verified.
Why a 39-mer is a demanding synthesis
Coupling efficiency compounds across every cycle. At 99% per step, thirty-eight couplings finish around 68% full-length before purification; at 98% it falls to about 46%. Add the conjugation chemistry for the lipid and linker, and retatrutide is among the more difficult syntheses in the catalogue, which is directly relevant to what a purity figure means for it.
Comparison within the incretin family
Semaglutide at 4,114 Da carries a C18 diacid; tirzepatide at 4,813 Da carries a C20; retatrutide at approximately 4,731 Da also carries a C20. All three are lipidated peptides of similar size built for the same reason, and their handling characteristics are correspondingly similar, which is more useful to know than any single figure.
Frequently asked questions
Why is retatrutide more surface-active than other peptides?
Its fatty-acid chain makes it amphipathic, actively driving it to air-liquid interfaces where peptides denature. Foaming matters more here.
Can it be quantified at 280 nm?
Yes. At 39 residues on a GIP scaffold it contains aromatic residues, unlike several shorter peptides in this library.
Is 39 residues a hard synthesis?
Yes. At 99% coupling efficiency per step, thirty-eight couplings finish around 68% full-length before purification.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedJaradat DMM, Thirteen decades of peptide synthesis. Amino Acids 2018 (PMID 29185032)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Tirzepatide (CID 166567236)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- What Is a Triple Agonist?One molecule activating three receptors. Why that differs from combination therapy, and what it buys and costs relative to giving three drugs.
- Retatrutide: Spellings, Codes and What Each FindsRetatrutide, LY3437943, reta. Which term finds the science, which finds the market, and the two Lilly codes easily confused with it.
- The History of RetatrutideFrom the 2022 Cell Metabolism discovery paper through Phase 2 in NEJM to the TRIUMPH Phase 3 readouts of 2026 and a signalled FDA filing.
- Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPHRetatrutide trial timeline: Phase 1 in 2020, Phase 2 in NEJM 2023, Phase 3 TRIUMPH readouts December 2025 to July 2026, FDA filing signalled for Q1 2027.
- Who Develops Retatrutide?Eli Lilly, under the code LY3437943. Why that matters for reading trial data, and why no licensed retatrutide product exists.